Human respiratory syncytial virus primary prevention

Revision as of 20:37, 26 September 2012 by Esther Lee (talk | contribs)
Jump to navigation Jump to search

Human respiratory syncytial virus Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Human Respiratory Syncytial Virus from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Human respiratory syncytial virus primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Human respiratory syncytial virus primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Human respiratory syncytial virus primary prevention

CDC on Human respiratory syncytial virus primary prevention

Human respiratory syncytial virus primary prevention in the news

Blogs on Human respiratory syncytial virus primary prevention

Directions to Hospitals Treating Human respiratory syncytial virus

Risk calculators and risk factors for Human respiratory syncytial virus primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Primary Prevention

As the virus is ubiquitous in all parts of the world, avoidance of infection is not possible. Epidemiologically, a vaccine would be the best answer. Unfortunately, vaccine development has been fraught with spectacular failure and with difficult obstacles. Researchers are working on a live, attenuated vaccine, but at present no vaccine exists. However, Palivizumab (brand name Synagis), a moderately effective prophylactic drug is available for infants at high risk. Palivizumab is a monoclonal antibody directed against RSV proteins. It is given by monthly injections, which are begun just prior to the RSV season and are usually continued for five months. RSV prophylaxis is indicated for infants that are premature or have either cardiac or lung disease.

References